Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 43.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,211 shares of the biopharmaceutical company’s stock after acquiring an additional 368 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $329,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in ALNY. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $26,000. Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC lifted its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $245.44 on Monday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The company has a 50 day moving average price of $267.01 and a 200 day moving average price of $249.57. The stock has a market capitalization of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the prior year, the company posted $1.15 EPS. The firm’s revenue for the quarter was down 33.3% on a year-over-year basis. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 over the last three months. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Finally, Raymond James raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.